



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes - Account Created in ScholarOne Manuscripts

1 message

Clinical Medicine Insights: Endocrinology and DiabetesTue, Jan 24, 2023 at
10:16 AM

<onbehalf@manuscriptcentral.com>

Reply-To: END@sagepub.com

To: arifa-m@fk.unair.ac.id

23-Jan-2023

Dear Dr. mustika:

Welcome to Clinical Medicine Insights: Endocrinology and Diabetes - ScholarOne Manuscripts site for online submission and review.

Your USER ID for your account at <https://mc.manuscriptcentral.com/end> is as follows:

USER ID: arifa-m@fk.unair.ac.id

If you are unsure of the password that you set when you created your account you should click the link below which will take you directly to the option for setting a new password.

https://mc.manuscriptcentral.com/end?URL_MASK=8ef17e0e78c54d52a977d6914ebb7a00

Please note that the single use link will expire on 27-Jan-2023 3:16:09 AM GMT / 26-Jan-2023 10:16:09 PM EST. If the single use link has expired, you can generate a single use password by entering your email address into the Password Help function on your site log in page: <https://mc.manuscriptcentral.com/end>

Please note that your PASSWORD is case-sensitive.

Thank you for your participation.

Sincerely,

Miss. Tanya Dobriyal

Clinical Medicine Insights: Endocrinology and Diabetes

END@sagepub.com

Log in to Remove This Account - https://mc.manuscriptcentral.com/end?URL_MASK=253d55d65d9d41b9ae001564b857b511



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes - Manuscript ID END-23-0031

1 message

Clinical Medicine Insights: Endocrinology and Diabetes

Mon, Feb 13, 2023 at

<onbehalf@manuscriptcentral.com>

9:49 PM

Reply-To: END@sagepub.com

To: arifa-m@fk.unair.ac.id, nurmawati-f@fk.unair.ac.id, nurulshahfiza@usm.my, nurlaili.susanti@kedokteran.uin-malang.ac.id

13-Feb-2023

Dear Dr. mustika:

Your manuscript entitled "Clinacanthus nutans L extracts reduce the serum level of Tumor Necrosis Factor- α , Malondialdehyde, Interleukin-6, and improve the Langerhans Islet area in Diabetic Rats Models" has been successfully submitted online and is presently being given full consideration for publication in Clinical Medicine Insights: Endocrinology and Diabetes.

Your manuscript ID is END-23-0031.

You have listed the following individuals as authors of this manuscript:
mustika, arifa; Fatimah, Nurmawati; Safitri, Indri; Noor, Nurul; Susanti, Nurlaili

You have listed the following contributions for each author:

CRedit Taxonomy

arifa mustika

Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing

Nurmawati Fatimah

Funding acquisition, Investigation, Resources, Software, Validation, Writing – original draft, Writing – review & editing

Indri Safitri

Conceptualization, Formal analysis, Investigation, Methodology, Supervision, Writing – original draft, Writing – review & editing

Nurul Noor

Formal analysis, Resources, Validation, Writing – original draft, Writing – review & editing

Nurlaili Susanti

Data curation, Formal analysis, Resources, Software, Supervision, Visualization, Writing – original draft, Writing – review & editing

If you have a query related to the contribution(s) listed against your name, please contact us within 7 days of receipt of this email. If your manuscript is accepted, we will be unable to make additions or changes to the contribution list, which will replace any contribution statement already present in the manuscript. Authors should use the Acknowledgements section for:

- Crediting any individuals with roles that do not constitute authorship
- Recognize a contribution(s) not covered by the taxonomy, including those of a named author

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/end> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/end>.

Please note that the journal can now publish video abstracts, infographics and plain language summaries (article publication enhancements) as part of your published article. Please note that you should revise your article according



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes - END-23-0031 has been unsubmitted

1 message

Clinical Medicine Insights: Endocrinology and DiabetesWed, Feb 15, 2023 at
7:19 PM

<onbehalf@manuscriptcentral.com>

Reply-To: END@sagepub.com

To: arifa-m@fk.unair.ac.id

15-Feb-2023

Dear Dr. mustika:

Your manuscript, END-23-0031, entitled "Clinacanthus nutans L extracts reduce the serum level of Tumor Necrosis Factor- α , Malondialdehyde, Interleukin-6, and improve the Langerhans Islet area in Diabetic Rats Models" has been unsubmitted to Clinical Medicine Insights: Endocrinology and Diabetes. It may either have been unsubmitted at your request or because you did not complete all necessary parts of the submission.

Please provide a complete title page. It should include the following:

- Manuscript title
- Authors/Co-author names and affiliations
- Corresponding Author
- Acknowledgements
- Declaration of Conflicting Interests
- Funding (Financial Disclosure)

Kindly upload a separate title page while you re-submit the manuscript.

Please login to <https://mc.manuscriptcentral.com/end> and click on the Author Center link. Click the 'Unsubmitted Manuscripts' link in the 'My Manuscripts' list. Find the returned manuscript and click 'Continue Submission'. You may make the necessary changes and submit the manuscript again. Please contact the Editorial Office if you have further questions.

Sincerely,
Miss. Tanya Dobriyal
Clinical Medicine Insights: Endocrinology and Diabetes
END@sagepub.com



arifa mustik <arifa-m@fk.unair.ac.id>

Decision on Clinical Medicine Insights: Endocrinology and Diabetes Manuscript END-23-0031

1 message

Clinical Medicine Insights: Endocrinology and Diabetes

<onbehalf@manuscriptcentral.com>

Reply-To: END@sagepub.com

To: arifa-m@fk.unair.ac.id

Tue, Apr 25, 2023 at 6:53 PM

25-Apr-2023

Dear Dr. mustika,

Manuscript ID END-23-0031 entitled "Clinacanthus nutans L extracts reduce the serum level of Tumor Necrosis Factor- α , Malondialdehyde, Interleukin-6, and improve the Langerhans Islet area in Diabetic Rats Models" which you submitted to Clinical Medicine Insights: Endocrinology and Diabetes, has been reviewed. The comments of the reviewer(s) and editor(s) are included at the bottom of this letter. Reviewer 1 has listed a number of study limitations, that should at least be fully acknowledged within the revised text.

The manuscript is not acceptable for publication in its current form. However, I invite you to revise the manuscript in accordance with the referee and editor comments below, and submit a revision.

Your revision is due on 25-May-2023. For your convenience, there is a calendar reminder attached to this email. If you are able to submit your revised paper sooner, please do so.

To revise your manuscript, log into <https://mc.manuscriptcentral.com/end> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You may also click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/end?URL_MASK=5256fb48efb947f1bd5a05ef1c241bc6

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Please also highlight the changes to your manuscript within the document by using the track changes mode in MS Word or by using colored text.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Center.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) and editor(s) in the space provided. You should complete the Author Response to Reviewers form (available here: <https://sagepub.com/response-to-reviewers-template>), answering point-by-point the questions raised and referencing the page numbers where the changes are implemented.

Please note that the journal can now publish video abstracts, infographics and plain language summaries (article publication enhancements) as part of your published article. Please note that you should revise your article according to the reviewers' comments before embarking on creation of an article enhancer, so that it reflects the revised version of your paper. However, if you plan to publish article enhancer(s) with your article, you must let your SAGE editor know as soon as possible, and definitely PRIOR TO ACCEPTANCE. For more information, including guidance on working with our professional vendor, please see the 'Article publication enhancements' section in our submission guidelines: <https://journals.sagepub.com/author-instructions/END>

In summary, you will need to submit the following:

- a clean, revised main document in doc. or docx.
- a highlighted, revised main document in doc. or docx.

- a completed Author Response to Reviewers form that includes all the reviewer comments you received in full and answers the questions raised by reviewers in doc. or docx.

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Once again, thank you for submitting your manuscript to Clinical Medicine Insights: Endocrinology and Diabetes and I look forward to receiving your revision.

Sincerely,

Nigel Irwin

Editor-in-Chief

Reviewer(s)' Comments to Author:

Reviewer: 1

Comments to the Author

The study aimed to investigate the effect of *C. nutans* leaf extract on oxidative stress and inflammation markers, as well as the area of Langerhans islets in diabetic rats. The results of the study showed that the administration of *C. nutans* leaf extract reduced the serum levels of MDA, TNF- α , and IL-6, which are markers of oxidative stress and inflammation, in diabetic rats. The findings suggest that *C. nutans* leaf extract may have therapeutic potential in reducing the damaging effects of oxidative stress and inflammation in diabetes, potentially by protecting pancreatic β cells. This may lead to new therapeutic options for the treatment of diabetes mellitus. Overall, this study adds to the growing body of research on the potential use of natural products for diabetes treatment and highlights the importance of investigating the effects of traditional medicinal plants in scientific studies.

While the study provides valuable insights into the potential therapeutic effects of *C. nutans* leaf extract on diabetes mellitus, it also has some limitations that should be considered.

1. Firstly, the study was conducted on animal models, and it is uncertain whether the same results can be observed in human subjects. Further clinical studies will be needed to confirm the effects of *C. nutans* leaf extract on diabetes mellitus in humans.
2. Secondly, the study did not investigate the mechanisms by which *C. nutans* leaf extract exerts its effects on oxidative stress, inflammation, and Langerhans islets. Is it possible that the authors may determine the active compounds responsible for the therapeutic effects of *C. nutans* leaf extract and the pathways by which they exert their effects.
3. Thirdly, the study did not compare the effects of *C. nutans* leaf extract to other standard treatments for diabetes mellitus, such as insulin therapy or oral hypoglycemic drugs. Further research is needed to determine whether *C. nutans* leaf extract can be used as a stand-alone treatment or as a complementary therapy to other diabetes treatments.
4. Finally, the study did not investigate potential side effects or toxicity of *C. nutans* leaf extract. It is essential to determine the safety of *C. nutans* leaf extract before it can be used as a therapeutic option for diabetes mellitus.

Reviewer: 2

Comments to the Author

The authors have demonstrated a promising antidiabetic property of *C. nutans* leaves extract. However, the whole manuscript should be checked for its English accuracy to improve its quality. Besides that, the discussion should be more in-depth.

Other comments:

1. More details are needed for the Materials and Methods - Plant Material preparation section, while some parts could be made clearer.
2. The term 'aimlessly split' should be changed to 'randomly assigned'.
3. Was there a group of normal non-diabetic rats used in the experiment? How do you ensure that the rats were induced successfully?
4. Please explain the slight increase of MDA in Cluster/Group 2 rats.
5. Please standardize the use of 'Cluster' or 'Group' in the text and figures.
6. Please provide the histopathologic appearance figures for all the clusters.

Editor's Comments to Author:

Associate Editor

Comments to the Author:

Thank you for submitting your manuscript to Clinical Medical Insights: Endocrinology and Diabetes. Please see our comments below:

- Please structure your manuscript with the sections outlined in the manuscript submission guidelines and restructure your abstract accordingly: <https://journals.sagepub.com/author-instructions/end>
- For Original Research: Background; Objectives; Design; Methods; Results; Conclusion; Registration (if applicable)

- Please add a declarations section after the conclusion with all the following statements as requested in the submission questions. Even where a statement may not be applicable they must be included and this clearly stated:

- Ethics approval and consent to participate
- Consent for publication
- Acknowledgments
- Funding
- Competing interests
- Availability of data and materials

- Please refer to the ARRIVE checklist, and submit a completed copy of this checklist with the revised paper as a supplementary file, indicating the page numbers on which the relevant items have been addressed:

<https://arriveguidelines.org/news/new-arrive-guidelines>

- The figure legends are quite brief, and we ask that you please add more detail. A figure legend should be thorough enough so that a reader can understand the main points of the figure without having to read the Materials and Methods and Results. For instructions on how to write a more complete figure legend please refer to this page:

<https://www.aje.com/arc/writing-effective-figure-legend/>.

- We strongly suggest that you have your manuscript edited for English language and grammar or to use a professional language editing service (to use our SAGE language service please click here: <http://languageservices.sagepub.com/en/services/editing/>) prior to submission to improve the grammar, spelling and punctuation of your manuscript and to enable, at the same time, the reviewers to focus exclusively on the scientific content of the manuscript.

Managing Editor comments to authors – please provide responses:

1. Please ensure that all of the following sections are present and complete at the end of your main manuscript under the heading 'Declarations', or add them if missing. If any of these sections are not applicable or not relevant to your study/article type, please still include the section subheading and simply put 'Not applicable' or 'None' underneath the subheading as appropriate. If you are unsure about what should be included in each of these sections, please refer to the journal's submission guidelines: <https://journals.sagepub.com/author-instructions/END>

a. Ethics approval and consent to participate – please ensure that you include the name of the IRB(s) as well as the ethical approval numbers/IDs, and a clear statement on patient/guardian/participant consent in the study. Please ensure that any relevant information contained elsewhere in your manuscript (e.g., in the methods section) is moved to this named section at the end of the article.

b. Consent for publication – please note that this section refers to patient/participant/guardian consent for publication (e.g., of patient images/data reported in a case report or case series), not author consent for publication.

c. Author contribution(s)

d. Acknowledgements

e. Funding

f. Conflict of interest statement

g. Availability of data and materials

2. Please note that at galley proof creation, any 'Author contributions' statement in your manuscript will be replaced by the CREDIT author contribution information that you provided on the online submission system (in which you detailed each author's contribution to each stage of this paper's development). Please therefore make sure that you move any additional statements that are not covered by the CREDIT information (e.g., medical writing assistance, crediting a colleague who is not listed as an author, or any other acknowledgement) into the 'Acknowledgements' section so that this information is not lost during galley proof creation.

3. Please note that if you or any of your co-authors wish to include your ORCID in the published manuscript, this must be done by each co-author by logging into the journal's submission site and linking their account with their ORCID prior to article acceptance. Instructions on this can be found here: https://scholaroneideas.secure.force.com/gethelpnow/Article_Page?id=kA11G0000000pub. We cannot publish ORCIDs that have only been included in the manuscript, each ORCID must have been linked to each co-author's journal submission site account.

4. Please check the manuscript submission guidelines for the journal and ensure your abstract is structured (if appropriate for your article type) using the correct subheadings as listed in the guidelines: <https://journals.sagepub.com/author-instructions/END>



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes - Manuscript ID END-23-0031.R1

1 message

Clinical Medicine Insights: Endocrinology and Diabetes

Wed, May 24, 2023 at 12:38 PM

<onbehalf@manuscriptcentral.com>

Reply-To: END@sagepub.com

To: arifa-m@fk.unair.ac.id, nurmawati-f@fk.unair.ac.id, indrisafiri@fk.unair.ac.id, nurlaili.susanti@kedokteran.uin-malang.ac.id, nurulshahfiza@usm.my

24-May-2023

Dear Dr. mustika:

Your revised manuscript entitled "Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor- α , Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models" has been successfully submitted online and is presently being given full consideration for publication in Clinical Medicine Insights: Endocrinology and Diabetes.

Your manuscript ID is END-23-0031.R1.

You have listed the following individuals as authors of this manuscript:
mustika, arifa; Fatimah, Nurmawati; Safitri, Indri; Susanti, Nurlaili; Noor, Nurul

You have listed the following contributions for each author:

CRedit Taxonomy

arifa mustika

Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing

Nurmawati Fatimah

Funding acquisition, Investigation, Resources, Software, Validation, Writing – original draft, Writing – review & editing

Indri Safitri

Conceptualization, Formal analysis, Investigation, Methodology, Supervision, Writing – original draft, Writing – review & editing

Nurlaili Susanti

Data curation, Formal analysis, Resources, Software, Supervision, Visualization, Writing – original draft, Writing – review & editing

Nurul Noor

Formal analysis, Resources, Validation, Writing – original draft, Writing – review & editing

If you have a query related to the contribution(s) listed against your name, please contact us within 7 days of receipt of this email. If your manuscript is accepted, we will be unable to make additions or changes to the contribution list, which will replace any contribution statement already present in the manuscript. Authors should use the Acknowledgements section for:

- Crediting any individuals with roles that do not constitute authorship
- Recognize a contribution(s) not covered by the taxonomy, including those of a named author

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/end> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/end>.

Please note that the journal can now publish video abstracts, infographics and plain language summaries (article publication enhancements) as part of your published article. Please note that you should revise your article according

to the reviewers' comments before embarking on creation of an article enhancer, so that it reflects the revised version of your paper. However, if you plan to publish article enhancer(s) with your article, you must let your SAGE editor know as soon as possible, and definitely PRIOR TO ACCEPTANCE. For more information, including guidance on working with our professional vendor, please see the 'Article publication enhancements' section in our submission guidelines: <https://journals.sagepub.com/author-instructions/END>

As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID (<https://orcid.org/>). We encourage all authors and co-authors to use ORCID iDs during the peer review process. If you have not already logged in to your account on this journal's ScholarOne Manuscripts submission site in order to update your account information and provide your ORCID identifier, we recommend that you do so at this time by logging in and editing your account information. In the event that your manuscript is accepted, only ORCID iDs validated within your account prior to acceptance will be considered for publication alongside your name in the published paper as we cannot add ORCID iDs during the Production steps. If you do not already have an ORCID iD you may login to your ScholarOne account to create your unique identifier and automatically add it to your profile.

Thank you for submitting your manuscript to Clinical Medicine Insights: Endocrinology and Diabetes.

Sincerely,
Sameer Khan
Clinical Medicine Insights: Endocrinology and Diabetes
END@sagepub.com



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes

4 messages

Clinical Medicine Insights: Endocrinology and Diabetes

<onbehalf@manuscriptcentral.com>

Reply-To: end@sagepub.com

To: arifa-m@fk.unair.ac.id

Mon, Jun 19, 2023 at
4:51 PM

19-Jun-2023

END-23-0031.R1 - Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor- α , Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models

Dear Dr. mustika:

Hope you are doing well.

Kindly provide the correct author response letter of your manuscript as your previous author response letter has a glitch as comments are overlapping

Looking forward to receiving the letter at the earliest.

If you have any further queries, please feel free to contact me.

Sincerely,
Mr. Sameer Khan
Clinical Medicine Insights: Endocrinology and Diabetes

Clinical Medicine Insights: Endocrinology and Diabetes

<onbehalf@manuscriptcentral.com>

Reply-To: end@sagepub.com

To: arifa-m@fk.unair.ac.id

Thu, Jun 22, 2023 at
1:52 PM

22-Jun-2023

END-23-0031.R1 - Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor- α , Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models

Dear Dr. mustika:

A gentle reminder if you have gone through my mail below.

Looking forward to your kind response.

Sincerely,

Mr. Sameer Khan
Clinical Medicine Insights: Endocrinology and Diabetes

[Quoted text hidden]

arifa mustik <arifa-m@fk.unair.ac.id>

To: end@sagepub.com

Mon, Jun 26, 2023 at 7:56 AM

Dear Mr. Sameer Khan

Thank you for your reminder
Where should I send a response letter revision? In this email or by the system?

Best Regards

[Quoted text hidden]

--

Dr. Arifa Mustika, MD.

Associate Professor in Pharmacology

Coordinator Master Program of Basic Medical Sciences

Faculty of Medicine. Universitas Airlangga

Prof. Dr. Moestopo street No 47 Surabaya. East Java, Indonesia

+6287851540939

Sameer Khan <sameer.khan@sagepub.in>

Mon, Jun 26, 2023 at 11:04 AM

To: arifa mustik <arifa-m@fk.unair.ac.id>

Dear Dr Mustika,

Thank you for your mail.

I would request you to kindly send the file to me via mail so I can process it further.

If you have any further queries, please feel free to contact me.

Sincerely,

Sameer-Khan



Sameer-Khan

Peer Review Associate

Suite 2426

Doon Express Business Park Road

Subhash Nagar

Sewla Khurd

Dehradun

Uttarakhand 248002

India

www.sagepub.in

Sage is a trading name of Sage Publications India Pvt Ltd. Reg. Delhi, India

CIN: U74899DL1981PTC012121Uttarakhand 248002

India

www.sagepub.in

Sage is a trading name of Sage Publications India Pvt. Ltd.

Reg. Delhi, India CIN: U74899DL1981PTC012121

-

From: arifa mustik <arifa-m@fk.unair.ac.id>

Sent: Monday, June 26, 2023 6:26 AM

To: END <END@sagepub.com>

Subject: Re: FW: Clinical Medicine Insights: Endocrinology and Diabetes

[EXTERNAL]

[Quoted text hidden]



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes

2 messages

Clinical Medicine Insights: Endocrinology and Diabetes

<onbehalf@manuscriptcentral.com>

Reply-To: end@sagepub.com

To: arifa-m@fk.unair.ac.id

Wed, Jun 28, 2023 at
3:50 PM

28-Jun-2023

END-23-0031.R1 - Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor- α , Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models

Dear Dr. mustika:

Hope you are doing well.

Kindly provide the correct author response letter of your manuscript by 2nd of July 2023 as your previous author response letter has a glitch as comments are overlapping

Looking forward to receiving the letter at the earliest.

If you have any further queries, please feel free to contact me.

Sincerely,
Mr. Sameer Khan
Clinical Medicine Insights: Endocrinology and Diabetes

arifa mustik <arifa-m@fk.unair.ac.id>

To: end@sagepub.com

Sat, Jul 1, 2023 at 9:37 AM

Dear Mr. Sameer Khan

I am sending my response letter according to the comment in the attachment.

Best Regards

[Quoted text hidden]

--

Dr. Arifa Mustika, MD.
Associate Professor in Pharmacology
Coordinator Master Program of Basic Medical Sciences
Faculty of Medicine. Universitas Airlangga
Prof. Dr. Moestopo street No 47 Surabaya. East Java, Indonesia
+6287851540939

 FINAL_010723_ARIFA_Response.docx
111K



arifa mustik <arifa-m@fk.unair.ac.id>

Decision on Clinical Medicine Insights: Endocrinology and Diabetes Manuscript END-23-0031.R1

1 message

Clinical Medicine Insights: Endocrinology and Diabetes <onbehalf@manuscriptcentral.com>

Mon, Jul 3, 2023 at 8:42 PM

Reply-To: END@sagepub.com

To: arifa-m@fk.unair.ac.id

03-Jul-2023

Dear Dr. mustika,

Manuscript ID END-23-0031.R1 entitled "Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor- α , Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models" which you submitted to Clinical Medicine Insights: Endocrinology and Diabetes, has been reviewed. The comments of the reviewer(s) and editor(s), if applicable, are included at the bottom of this letter.

The reviewers have recommended publication, but also suggest some minor revisions to your manuscript. As such, one of the reviewers has asked for some further clarifications. Therefore, I invite you to respond to the reviewer comments and revise your manuscript.

Your revision is due on 02-Aug-2023. For your convenience, there is a calendar reminder attached to this email. If you are able to submit your revised paper sooner, please do so.

To revise your manuscript, log into <https://mc.manuscriptcentral.com/end> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You may also click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/end?URL_MASK=5602f46bfa264ca9ad00a966d4f85428

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Please also highlight the changes to your manuscript within the document by using the track changes mode in MS Word or by using colored text.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Center.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) and editor(s) in the space provided. You should complete the Author Response to Reviewers form (available here: <https://sagepub.com/response-to-reviewers-template>), answering point-by-point the questions raised and referencing the page numbers where the changes are implemented.

Please note that the journal can now publish video abstracts, infographics and plain language summaries (article publication enhancements) as part of your published article. Please note that you should revise your article according to the reviewers' comments before embarking on creation of an article enhancer, so that it reflects the revised version of your paper. However, if you plan to publish article enhancer(s) with your article, you must let your Sage editor know as soon as possible, and definitely PRIOR TO ACCEPTANCE. For more information, including guidance on working with our professional vendor, please see the 'Article publication enhancements' section in our submission guidelines: <https://journals.sagepub.com/author-instructions/END>

In summary, you will need to submit the following:

- a clean, revised main document in doc. or docx.
- a highlighted, revised main document in doc. or docx.

- a completed Author Response to Reviewers form that includes all the reviewer comments you received in full and answers the questions raised by reviewers in doc. or docx.

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Because we are trying to facilitate timely publication of manuscripts submitted to Clinical Medicine Insights: Endocrinology and Diabetes, your revised manuscript should be uploaded as soon as possible. If it is not possible for you to submit your revision by the deadline, please contact the editorial office to arrange a new deadline.

Once again, thank you for submitting your manuscript to the Clinical Medicine Insights: Endocrinology and Diabetes and I look forward to receiving your revision.

Sincerely,

Nigel Irwin

Editor-in-Chief

Reviewer: 2

Comments to the Author

Thank you for the corrections and clarifications.

Line 82: What does it mean by "...determined from Balai Materia..."?

Line 109: "...assessed as diabetic and used..."

Figures 1 and 2 captions: Change "ministered" to "administered"

Line 246: ...elimination of...

Line 260: "Chronic toxicity." Typo or incomplete sentence?

Associate Editor

Comments to the Author:

-Please also include in the Methods the calculation and justification of the sample size selected for this study. If power analysis for sample size calculation was not done, then please include this as a limitation of this study in the Discussion.

-Please remove the limitations of this study from the conclusion section and ensure to include it the Discussion.

-Please ensure that you provide a more substantial Conclusion section relevant to the context of the study.

-Please ensure that, before resubmission, a person proficient in written English edits the manuscript. It is important that the message being conveyed in the manuscript is as unambiguous as possible.

Managing Editor comments to authors – please provide responses:

1. Please ensure that all of the following sections are present and complete at the end of your main manuscript under the heading 'Declarations', or add them if missing. If any of these sections are not applicable or not relevant to your study/article type, please still include the section subheading and simply put 'Not applicable' or 'None' underneath the subheading as appropriate. If you are unsure about what should be included in each of these sections, please refer to the journal's submission guidelines: <https://journals.sagepub.com/author-instructions/END>

a. Ethics approval and consent to participate – please ensure that you include the name of the IRB(s) as well as the ethical approval numbers/IDs, and a clear statement on patient/guardian/participant consent in the study. Please ensure that any relevant information contained elsewhere in your manuscript (e.g., in the methods section) is moved to this named section at the end of the article.

b. Consent for publication – please note that this section refers to patient/participant/guardian consent for publication (e.g., of patient images/data reported in a case report or case series), not author consent for publication.

c. Author contribution(s)

d. Acknowledgements

e. Funding

f. Conflict of interest statement

g. Availability of data and materials

2. Please note that at galley proof creation, any 'Author contributions' statement in your manuscript will be replaced by the CREDIT author contribution information that you provided on the online submission system (in which you detailed each author's contribution to each stage of this paper's development). Please therefore make sure that you move any additional statements that are not covered by the CREDIT information (e.g., medical writing assistance, crediting a colleague who is not listed as an author, or any other acknowledgement) into the 'Acknowledgements' section so that this information is not lost during galley proof creation.
3. Please note that if you or any of your co-authors wish to include your ORCID in the published manuscript, this must be done by each co-author by logging into the journal's submission site and linking their account with their ORCID prior to article acceptance. Instructions on this can be found here: https://scholaroneideas.secure.force.com/gethelpnow/Article_Page?id=kA11G0000000pub. We cannot publish ORCID that have only been included in the manuscript, each ORCID must have been linked to each co-author's journal submission site account.
4. Please check the manuscript submission guidelines for the journal and ensure your abstract is structured (if appropriate for your article type) using the correct subheadings as listed in the guidelines: <https://journals.sagepub.com/author-instructions/END>



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes - END-23-0031.R2 has been unsubmitted from Clinical Medicine Insights: Endocrinology and Diabetes

1 message

Clinical Medicine Insights: Endocrinology and Diabetes

Sat, Jul 15, 2023 at

<onbehalf@manuscriptcentral.com>

4:35 AM

Reply-To: END@sagepub.com

To: arifa-m@fk.unair.ac.id

14-Jul-2023

Dear Dr. Mustika,

Your manuscript, END-23-0031.R2, entitled 'Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor- α , Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models' has been unsubmitted from Clinical Medicine Insights: Endocrinology and Diabetes.

Before you resubmit the revised manuscript, please ensure that you provide a more substantial Conclusion section relevant to the context of the study (upto 150 words).

To resubmit, please login to <https://mc.manuscriptcentral.com/end> and click on the Author Center link. Click the 'Unsubmitted Manuscripts' link in the 'My Manuscripts' list. Find the returned manuscript and click 'Continue Submission'.

Please contact the Editorial Office if you have further questions.

Sincerely

Clinical Medicine Insights: Endocrinology and Diabetes Editorial Office

END@sagepub.com



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes - END-23-0031.R2 has been unsubmitted from Clinical Medicine Insights: Endocrinology and Diabetes

2 messages

Clinical Medicine Insights: Endocrinology and Diabetes

<onbehalf@manuscriptcentral.com>

Reply-To: END@sagepub.com

To: arifa-m@fk.unair.ac.id

Thu, Jul 20, 2023 at

6:52 PM

20-Jul-2023

Dear Dr. Mustika,

Your manuscript, END-23-0031.R2, entitled 'Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor- α , Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models' has been unsubmitted from Clinical Medicine Insights: Endocrinology and Diabetes.

Before you resubmit the revised manuscript, please address the following points:

-Please clarify the discrepancy in the manuscript as 53 references are provided in the references section while only 52 in-text citations are provided in the main document. Also, please ensure the in-text citations (main document) and the list of references are consistent as discrepancy is identified (Abdul Wahid et al. [2017]).

Please ensure that all the references are accurately provided and cited chronologically beginning Introduction section in the main document as some missing in-text citations are identified.

To resubmit, please login to <https://mc.manuscriptcentral.com/end> and click on the Author Center link. Click the 'Unsubmitted Manuscripts' link in the 'My Manuscripts' list. Find the returned manuscript and click 'Continue Submission'.

Please contact the Editorial Office if you have further questions.

Sincerely

Clinical Medicine Insights: Endocrinology and Diabetes Editorial Office

arifa mustik <arifa-m@fk.unair.ac.id>

To: END@sagepub.com

Fri, Jul 21, 2023 at 2:41 PM

Dear Clinical Medicine Insights: Endocrinology and Diabetes Editorial Office

I apologize, because I already resubmitted the manuscript by the system before it was corrected carefully. Therefore, In this email, I attach my main document revision
Thank you very much

Sincerely,

[Quoted text hidden]

--

Dr. Arifa Mustika, MD.

Associate Professor in Pharmacology

Coordinator Master Program of Basic Medical Sciences

Faculty of Medicine. Universitas Airlangga

Prof. Dr. Moestopo street No 47 Surabaya. East Java, Indonesia

+6287851540939

2 attachments**ARIFA_REVISE 3_CLEAN_ MANUSCRIPT_110723.docx**

103K



ARIFA_REVISE 3_HIGHLIGHT_ MANUSCRIPT_110723.docx

104K



arifa mustik <arifa-m@fk.unair.ac.id>

Clinical Medicine Insights: Endocrinology and Diabetes - Decision on Manuscript ID END-23-0031.R2

1 message

Clinical Medicine Insights: Endocrinology and DiabetesThu, Jul 27, 2023 at
6:18 PM

<onbehalf@manuscriptcentral.com>

Reply-To: n.irwin@ulster.ac.uk

To: arifa-m@fk.unair.ac.id

27-Jul-2023

Dear Dr. mustika:

It is a pleasure to accept your manuscript entitled "Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor- α , Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models" in its current form for publication in Clinical Medicine Insights: Endocrinology and Diabetes. The comments of the reviewer(s) who reviewed your manuscript are included at the foot of this letter.

Thank you for your fine contribution. On behalf of the Editors of Clinical Medicine Insights: Endocrinology and Diabetes, we look forward to your continued contributions to the Journal.

Sincerely,
Dr. Nigel Irwin
Clinical Medicine Insights: Endocrinology and Diabetes
n.irwin@ulster.ac.uk

Reviewer(s)' Comments to Author:

Associate Editor(s)' Comments to Author:

Associate Editor: A, Tejaswini
Comments to the Author:
(There are no comments.)



arifa mustik <arifa-m@fk.unair.ac.id>

Page proofs for "Clinical Medicine Insights: Endocrinology and Diabetes" - END 1196462

1 message

SAGE Proofs <sageedit.proofs@candmdigitals.com>

Mon, Aug 28, 2023 at 7:07 PM

Reply-To: end_sagepub@candmdigitals.com, sagepub@candmdigitals.com, bcc-mail@candmdigitals.com

To: arifa-m@fk.unair.ac.id

Cc: end_sagepub@candmdigitals.com, Sophie.Maprayil@sagepub.co.uk

Dear Arifa Mustika,

We have prepared your article for publication in *Clinical Medicine Insights: Endocrinology and Diabetes*, and it is ready for your final review in SAGE Edit:

<https://emxpert.net/sageedit/journals/?token=7C5DE768-1E68-4ADC-8>

Please review your proof carefully and submit your corrections or approval via SAGE Edit within the next **2 business days**. Only changes consistent with the journal's style and peer review policies will be implemented; extensive changes after peer review are generally not accepted, and may incur a fee if accepted.

Please note that this is your final opportunity to ensure your article's accuracy, and post-publication changes may not be possible, as explained in our [Corrections Policy](#). Please let me know if you need any further assistance.

END Journals Production

Sage Publishing

Email: end_sagepub@candmdigitals.com